Physician profile
Dawit Zemichael
NPI 1164511317
$1,904.35
in general payments reported to CMS, 2019-2025
19 companies · $186 in 2025
The $186 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $784 · 2020: $150 · 2021: $192 · 2022: $211 · 2023: $120 · 2024: $260 · 2025: $186.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $567.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $566.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $652.22 | 2019-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $256.73 | 2019-2023 | Ingrezza |
| Sunovion Pharmaceuticals INC. | $214.50 | 2019-2020 | |
| Axsome Therapeutics, INC. | $199.75 | 2023-2025 | Auvelity |
| Abbvie INC. | $119.59 | 2022-2025 | Vraylar |
| Ironshore Pharmaceuticals INC. | $81.57 | 2019 | |
| Indivior INC. | $65.38 | 2019-2020 | |
| Lundbeck LLC | $65.28 | 2019-2022 | |
| Allergan, INC. | $48.29 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $46.79 | 2019 | |
| Janssen Pharmaceuticals, INC | $25.98 | 2024 | Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $25.78 | 2021-2022 | |
| Almatica Pharma LLC | $18.04 | 2023 | Sertraline Hcl, Loreev Xr |
| Eisai INC. | $16.27 | 2021 | |
| Orexo US, INC. | $15.37 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuronetics, INC. | $15.07 | 2019 | |
| Corium, LLC | $14.37 | 2022 | |
| Jazz Pharmaceuticals INC. | $12.32 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $11.05 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dawit Zemichael listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.